• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

疫苗接种率最高的国家与世界其他国家之间新冠肺炎病例死亡率的不均衡情况。

The disproportionate case-fatality ratio of COVID-19 between countries with the highest vaccination rates and the rest of the world.

作者信息

Haider Najmul, Hasan Mohammad Nayeem, Guitian Javier, Khan Rumi A, McCoy David, Ntoumi Francine, Dar Osman, Ansumana Rashid, Uddin Md Jamal, Zumla Alimuddin, Kock Richard A

机构信息

The Royal Veterinary College, University of London, Hatfield, UK.

School of Life Sciences, Keele University, Keele, UK.

出版信息

IJID Reg. 2023 Mar;6:159-166. doi: 10.1016/j.ijregi.2023.01.011. Epub 2023 Jan 26.

DOI:10.1016/j.ijregi.2023.01.011
PMID:36721772
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9881127/
Abstract

OBJECTIVES

The global reported cumulative case-fatality ratios (rCFRs) and excess mortality rates of the 20 countries with the highest coronavirus disease 2019 (COVID-19) vaccination rates, the rest of the world and Sub-Saharan Africa (SSA) were compared before and after the commencement of vaccination programmes.

METHODS

A time series model was used to understand the trend of rCFR over time, and a generalized linear mixed model was used to understand the effect of vaccination on rCFR.

RESULTS

By 31 December 2022, an average of 260.3 doses of COVID-19 vaccine per 100 population had been administered in the top 20 vaccinated countries, compared with 152.1 doses in the rest of the world and 51.2 doses in SSA. The mean rCFR of COVID-19 had decreased by 69.0% in the top 20 vaccinated countries, 26.5% in the rest of the world and 7.6% in SSA. Excess mortality had decreased by 48.7% in the top 20 vaccinated countries, compared with 62.5% in the rest of the world and 60.7% in SSA. In a generalized linear mixed model, the reported number of vaccine doses administered (/100 population) (odds ratio 0.64) was associated with a steeper reduction in COVID-19 rCFR.

CONCLUSIONS

Vaccine equity and faster roll-out across the world is critically important in reducing COVID-19 transmission and CFR.

摘要

目的

比较20个新冠病毒病2019(COVID-19)疫苗接种率最高的国家、世界其他地区和撒哈拉以南非洲(SSA)在疫苗接种计划开始前后的全球报告累积病死率(rCFRs)和超额死亡率。

方法

使用时间序列模型了解rCFR随时间的变化趋势,并使用广义线性混合模型了解疫苗接种对rCFR的影响。

结果

截至2022年12月31日,20个疫苗接种率最高的国家每100人平均接种了260.3剂COVID-19疫苗,世界其他地区为152.1剂,SSA为51.2剂。20个疫苗接种率最高的国家中COVID-19的平均rCFR下降了69.0%,世界其他地区下降了26.5%,SSA下降了7.6%。20个疫苗接种率最高的国家超额死亡率下降了48.7%,世界其他地区为62.5%,SSA为60.7%。在广义线性混合模型中,报告的疫苗接种剂量数(/100人口)(优势比0.64)与COVID-19 rCFR的更显著下降相关。

结论

全球范围内的疫苗公平性和更快的推广对于减少COVID-19传播和病死率至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ae1/9982601/069ceec09847/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ae1/9982601/dd4c40935b0d/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ae1/9982601/24500dddc4cc/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ae1/9982601/0f4bc7f88164/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ae1/9982601/069ceec09847/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ae1/9982601/dd4c40935b0d/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ae1/9982601/24500dddc4cc/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ae1/9982601/0f4bc7f88164/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ae1/9982601/069ceec09847/gr4.jpg

相似文献

1
The disproportionate case-fatality ratio of COVID-19 between countries with the highest vaccination rates and the rest of the world.疫苗接种率最高的国家与世界其他国家之间新冠肺炎病例死亡率的不均衡情况。
IJID Reg. 2023 Mar;6:159-166. doi: 10.1016/j.ijregi.2023.01.011. Epub 2023 Jan 26.
2
The Global Case-Fatality Rate of COVID-19 Has Been Declining Since May 2020.自 2020 年 5 月以来,全球 COVID-19 的病死率一直在下降。
Am J Trop Med Hyg. 2021 Apr 21;104(6):2176-2184. doi: 10.4269/ajtmh.20-1496.
3
A SARS-CoV-2 Surveillance System in Sub-Saharan Africa: Modeling Study for Persistence and Transmission to Inform Policy.撒哈拉以南非洲的新冠病毒监测系统:关于持续存在和传播以指导政策的建模研究
J Med Internet Res. 2020 Nov 19;22(11):e24248. doi: 10.2196/24248.
4
Emerging Variants of SARS-CoV-2 and Novel Therapeutics Against Coronavirus (COVID-19)严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的新变种及针对冠状病毒(COVID-19)的新型疗法
5
Disparities and effectiveness of COVID-19 vaccine policies in three representative European countries.三个代表性欧洲国家的 COVID-19 疫苗政策的差异和效果。
Int J Equity Health. 2024 Jan 30;23(1):16. doi: 10.1186/s12939-024-02110-w.
6
COVID-19 Statistics in the Arab World by the End of October 2022: A Cross-Sectional Study.2022年10月底阿拉伯世界的新冠疫情统计:一项横断面研究。
Cureus. 2022 Dec 18;14(12):e32670. doi: 10.7759/cureus.32670. eCollection 2022 Dec.
7
Temporal changes to adult case fatality risk of COVID-19 after vaccination in England between May 2020 and February 2022: a national surveillance study.2020 年 5 月至 2022 年 2 月期间,英国接种疫苗后 COVID-19 成人病死率的时间变化:一项全国性监测研究。
J R Soc Med. 2024 Jun;117(6):202-211. doi: 10.1177/01410768231216332. Epub 2023 Dec 14.
8
Implementing national COVID-19 vaccination programmes in sub-Saharan Africa- early lessons from Zimbabwe: a descriptive cross-sectional study.在撒哈拉以南非洲实施国家 COVID-19 疫苗接种计划——津巴布韦的早期经验:一项描述性的横断面研究。
Pan Afr Med J. 2021 Nov 24;40:180. doi: 10.11604/pamj.2021.40.180.30824. eCollection 2021.
9
Country-specific determinants for COVID-19 case fatality rate and response strategies from a global perspective: an interpretable machine learning framework.从全球视角看 COVID-19 病死率的国家特有决定因素和应对策略:一个可解释的机器学习框架。
Popul Health Metr. 2024 Jun 3;22(1):10. doi: 10.1186/s12963-024-00330-4.
10
Assessing the impacts of COVID-19 vaccination programme's timing and speed on health benefits, cost-effectiveness, and relative affordability in 27 African countries.评估 27 个非洲国家 COVID-19 疫苗接种计划的时间和速度对健康效益、成本效益和相对可负担性的影响。
BMC Med. 2023 Mar 8;21(1):85. doi: 10.1186/s12916-023-02784-z.

引用本文的文献

1
Excess Mortality and its Determinants During the COVID-19 Pandemic in 21 Countries: An Ecological Study from the C-MOR Project, 2020 and 2021.21个国家在2020年和2021年新冠疫情期间的超额死亡率及其决定因素:C-MOR项目的一项生态学研究
J Epidemiol Glob Health. 2024 Dec;14(4):1650-1661. doi: 10.1007/s44197-024-00320-7. Epub 2024 Nov 11.
2
Simple statistical insights into the COVID-19 data of Saudi Arabia: figures prior to vaccination campaign.对沙特阿拉伯新冠疫情数据的简单统计洞察:疫苗接种运动之前的数据。
F1000Res. 2021 Aug 4;10:410. doi: 10.12688/f1000research.52600.2. eCollection 2021.
3
Comprehensive Review of COVID-19: Epidemiology, Pathogenesis, Advancement in Diagnostic and Detection Techniques, and Post-Pandemic Treatment Strategies.

本文引用的文献

1
Sero-prevalence of anti-SARS-CoV-2 antibodies among communities between July and August 2022 in Bangui, Central African Republic.2022年7月至8月期间,中非共和国班吉各社区抗新冠病毒2抗体的血清流行率。
J Public Health Afr. 2023 Jun 5;14(8):2315. doi: 10.4081/jphia.2023.2315. eCollection 2023 Aug 7.
2
Differences in case-fatality-rate of emerging SARS-CoV-2 variants.新型严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变体的病死率差异。
Public Health Pract (Oxf). 2023 Jun;5:100350. doi: 10.1016/j.puhip.2022.100350. Epub 2022 Dec 10.
3
Global impact of the first year of COVID-19 vaccination: a mathematical modelling study.
新型冠状病毒肺炎(COVID-19)的全面综述:流行病学、发病机制、诊断和检测技术的进展,以及大流行后的治疗策略。
Int J Mol Sci. 2024 Jul 26;25(15):8155. doi: 10.3390/ijms25158155.
4
Scenario-based assessment of emergency management of urban infectious disease outbreaks.基于情景的城市传染病疫情应急管理评估。
Front Public Health. 2024 Apr 24;12:1368154. doi: 10.3389/fpubh.2024.1368154. eCollection 2024.
5
ution of the data and methods in real-world COVID-19 vaccine effectiveness studies on mortality: a oping eview protocol.在真实世界 COVID-19 疫苗效果研究中关于死亡率的数据和方法的评价:一项系统综述方案。
BMJ Open. 2024 Mar 19;14(3):e079071. doi: 10.1136/bmjopen-2023-079071.
6
Prevalence of post-traumatic stress disorder risk post-COVID-19 in 12 countries in Latin America: a cross-sectional survey.新冠后(post-COVID-19)在拉丁美洲 12 个国家的创伤后应激障碍风险的流行率:一项横断面调查。
Front Public Health. 2024 Jan 8;11:1302694. doi: 10.3389/fpubh.2023.1302694. eCollection 2023.
全球首例 COVID-19 疫苗接种一年的影响:一项数学建模研究。
Lancet Infect Dis. 2022 Sep;22(9):1293-1302. doi: 10.1016/S1473-3099(22)00320-6. Epub 2022 Jun 23.
4
Seroprevalence of anti-SARS-CoV-2 antibodies in a population living in Bomassa village, Republic of Congo.刚果共和国博马萨村人群中抗新冠病毒 2 抗体的血清阳性率。
IJID Reg. 2022 Mar;2:130-136. doi: 10.1016/j.ijregi.2022.01.002. Epub 2022 Jan 15.
5
Understanding chaos in COVID-19 and its relationship to stringency index: Applications to large-scale and granular level prediction models.理解 COVID-19 中的混沌及其与严格指数的关系:在大规模和细粒度预测模型中的应用。
PLoS One. 2022 Jun 8;17(6):e0268023. doi: 10.1371/journal.pone.0268023. eCollection 2022.
6
Protection against the Omicron Variant from Previous SARS-CoV-2 Infection.既往感染严重急性呼吸综合征冠状病毒2对奥密克戎变异株的防护作用。
N Engl J Med. 2022 Mar 31;386(13):1288-1290. doi: 10.1056/NEJMc2200133. Epub 2022 Feb 9.
7
Covid-19: Fourth vaccine doses-who needs them and why?新冠疫情:第四剂疫苗——谁需要接种以及为何要接种?
BMJ. 2022 Jan 7;376:o30. doi: 10.1136/bmj.o30.
8
Evidence for a mouse origin of the SARS-CoV-2 Omicron variant.支持 SARS-CoV-2 奥密克戎变体源自鼠类的证据。
J Genet Genomics. 2021 Dec;48(12):1111-1121. doi: 10.1016/j.jgg.2021.12.003. Epub 2021 Dec 24.
9
Differences in the case fatality risks associated with SARS-CoV-2 Delta and non-Delta variants in relation to vaccine coverage: An early ecological study in the United Kingdom.与疫苗接种覆盖率相关的 SARS-CoV-2 德尔塔变体和非德尔塔变体的病例病死率风险差异:英国的一项早期生态学研究。
Infect Genet Evol. 2022 Jan;97:105162. doi: 10.1016/j.meegid.2021.105162. Epub 2021 Nov 27.
10
SARS-CoV-2 exposure in Malawian blood donors: an analysis of seroprevalence and variant dynamics between January 2020 and July 2021.马拉维献血者中SARS-CoV-2暴露情况:2020年1月至2021年7月血清流行率及病毒变异动态分析
BMC Med. 2021 Nov 19;19(1):303. doi: 10.1186/s12916-021-02187-y.